Hanmi CEO Sae-Chang Kwon, “We applied FDA approval for Rolontis and Olita’s Phase III clinical trial”
Hanmi Pharm(CEO Sae-Chang Kwon) has set the ‘Hanmi Innovative Management to Become Pharmaceutical Power’ ’as their new year’s resolution.
“During my more than 20-year career at Hanmi, I’ve always done a new thing every year, not the same work,” said CEO Sae-Chang Kwon, “As I take our R&D work as...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.